Topline results from the MUSCLE study indicate that ulviprubart did not meet its primary endpoint of mean change in inclusion body myositis functional rating scale scores.
Abcuro, Inc., today announced topline results from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results